Royalty Report: Medical, Device, Pain – Collection: 287067

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Medical
  • Device
  • Pain
  • Surgical
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 287067

License Grant
The terms of a Contribution and Royalty Agreement is assumed in the Merger with another Party.  This agreement provides for the Company to pay Licensor, an individual and founder of Licensee, royalties on revenues earned from sales of any and all products derived from the use of the DenerveX technology.
License Property
The DenerveX® System is a potential solution designed to provide these patients with long-term relief through a minimally invasive procedure with little downtime.

DenerveX® System is a device that is inserted into the facet joint through a small incision during the procedure. It uses heat and light tissue scraping action on the back of the facet joint to disrupt pain signals. Patients typically recover from the procedure and are back to their everyday activities within 2 weeks.

Field of Use
DenerveXâ„¢ System is a new and novel device designed for enduring relief of Facet Joint Syndrome related to back pain.

Licensee is a healthcare medical biosciences company that develops and implements advanced innovative treatment options in regenerative medicine to treat an array of debilitating medical conditions. The Company is also in the business of designing and marketing proprietary medical devices for commercial use.

IPSCIO Record ID: 4603

License Grant
Contributor, an individual, does hereby irrevocably contribute, transfer, assign and convey to Corporation, its successors and assigns, free and clear of any Encumbrances, to have and hold forever, all of Contributor's right, title and interest in and good and marketable title to the Contributed Assets.
License Property
The Licensor invented the DenerveX technology for use in the field of FJS, also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis. The System consists of single use device and a reusable dedicated power generator. The system works exclusively in precise synchronization for therapy delivery for patients with facet joint pain.

'Contributed Assets' means the (i) Patent; and (ii) all Intellectual Property Rights described in, related to or associated with the Patent, including without limitation, all Intellectual Property Rights in and to and all rights to Practice the Debrider Device and the Intellectual Property Rights described in or evidenced by the Patent; and (iii) all Know-How and all technical and other information that is necessary, useful, or convenient to Practice the Debrider Device or the Intellectual Property Rights described in or evidenced by the Patent, in each case to the extent owned or held by Contributor as of the Effective Date.

The Patent and all Intellectual Property Rights described in, related to or associated with the Patent, including without limitation, all Intellectual Property Rights in and to and all rights to Practice the Device and the Intellectual Property Rights described in or evidenced by the Patent; and all Know-How and all technical and other information that is necessary, useful, or convenient to Practice the Device or the Intellectual Property Rights described in or evidenced by the Patent, in each case to the extent owned or held by Contributor as of the Effective Date.

Patent means United States Patent No. US 8,167,879 B2 issued May 1, 2012, and all continuations, continuations-in-part, divisions, re-examinations, and reissues thereof, and any corresponding foreign patents and foreign patent applications currently filed or filed in the future and any patent rights issuing, granted or registered thereon.

Field of Use
Medical device is namely rotational denervation cautery devices for the treatment of facet joint syndrome.

The present invention relates to spinal medical procedures.

Methods and surgical tools for treating back pain use a spinal facet debridement tool with cautery and denuding action and minimally invasive protocol that can denude and cauterize soft tissue associated with a synovial capsule of the spinal facet joint.

IPSCIO Record ID: 25856

License Grant
The Licensee entered into a License Agreement with the Licensee for a License in the field of medicine for certain intellectual property rights related to low friction and low wear polymer composites. By its terms, the License Agreement continues until all of the Licensed patents have expired, which, based on the Licensed presently pending patent applications, is currently estimated to be August 2024.
License Property
The System includes an interactive haptic robotics platform that utilizes tactile-guided robotics and patient-specific visualization to prepare the knee joint for the insertion and alignment of our resurfacing implants through a keyhole incision in a minimally invasive, bone-preserving and tissue-sparing procedure.
Field of Use
The field of use is medicine.

The Licensee is a medical device company that markets advanced robotic solution and implants for minimally invasive orthopedic knee procedures. They offer an innovative, restorative surgical solution that enables orthopedic surgeons to consistently, reproducibly and precisely treat patient-specific, early to mid-stage osteoarthritic knee disease that is performed using proprietary, U.S. Food and Drug Administration, or FDA, cleared system.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.